Last 12 months
Inside the activity.
0 purchase rows · 10 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 19, 2018 Filed Oct 23, 2018 17:31 UTC |
Powell LynneSenior VP - CCO
|
SaleCommon Stock | 100 | $7.50 | $750.00 |
DisclosureSEC source: 0001127602-18-030769 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,149 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 12 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,455 Underlying: Common Stock · 100 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 972 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 11 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,927 Underlying: Common Stock · 972 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 100 | $7.45 | $745.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 8 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 100 | $3.78 | $378.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 7 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 972 | $7.26 | $7,056.72 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 6 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.25 to $7.26. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 972 | $3.22 | $3,129.84 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 5,528 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 10 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,899 Underlying: Common Stock · 5,528 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 9 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,555 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 5,528 | $7.27 | $40,188.56 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.25 to $7.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 5,528 | $3.22 | $17,800.16 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $7.19 | $23,367.50 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.10 to $7.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 14:07 UTC |
Sheridan William PSenior VP - CMO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-18-025155 · form4.xml · derivative · entry 3 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 14:07 UTC |
Sheridan William PSenior VP - CMO
|
SaleCommon Stock | 62,500 | $7.03 | $439,375.00 |
DisclosureSEC source: 0001127602-18-025155 · form4.xml · nonDerivative · entry 2 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,213 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.00 to $7.16. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 14:07 UTC |
Sheridan William PSenior VP - CMO
|
Exercise / conversionCommon Stock | 62,500 | $1.42 | $88,750.00 |
DisclosureSEC source: 0001127602-18-025155 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:40 UTC |
LEE KENNETH B JRDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021734 · form4.xml · derivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:38 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021732 · form4.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:35 UTC |
Hutson Nancy JDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021730 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:32 UTC |
Erck Stanley CDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021728 · form4.xml · derivative · entry 1 Erck Stanley C · CIK 0001342826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:29 UTC |
Cohen Fred EDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021726 · form4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:25 UTC |
ABERCROMBIE GEORGE BDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021724 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 18:54 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 2,916 | $6.43 | $18,749.88 |
DisclosureSEC source: 0001127602-18-019690 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,818 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 18:48 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 1,555 | $6.43 | $9,998.65 |
DisclosureSEC source: 0001127602-18-019686 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,702 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 19:07 UTC |
Sheridan William PSenior VP - CMO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 42,112 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001127602-18-019981 · form4.xml · derivative · entry 3 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,112 shares Expires 2018-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 19:07 UTC |
Sheridan William PSenior VP - CMO
|
SaleCommon Stock | 42,112 | $6.30 | $265,305.60 |
DisclosureSEC source: 0001127602-18-019981 · form4.xml · nonDerivative · entry 2 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,058 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017 and due to the upcoming expiry of the option. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.23 to $6.46. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 19:07 UTC |
Sheridan William PSenior VP - CMO
|
Exercise / conversionCommon Stock | 42,112 | $2.58 | $108,648.96 |
DisclosureSEC source: 0001127602-18-019981 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017 and due to the upcoming expiry of the option. Read SEC document |
| May 17, 2018 Filed May 21, 2018 13:31 UTC |
Stonehouse Jon PDirector · President & CEO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 70,427 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-18-018216 · form4.xml · derivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,573 Underlying: Common Stock · 70,427 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 13:31 UTC |
Stonehouse Jon PDirector · President & CEO
|
Exercise / conversionCommon Stock | 70,427 | $1.42 | $100,006.34 |
DisclosureSEC source: 0001127602-18-018216 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 13:25 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-18-017800 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,132 Underlying: Common Stock · 12,500 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 13:25 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Tax withholdingCommon Stock | 3,004 | $5.91 | $17,753.64 |
DisclosureSEC source: 0001127602-18-017800 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,264 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| May 15, 2018 Filed May 17, 2018 13:25 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Exercise / conversionCommon Stock | 12,500 | $1.42 | $17,750.00 |
DisclosureSEC source: 0001127602-18-017800 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 9,378 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · derivative · entry 6 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,378 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 20,622 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · derivative · entry 5 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,622 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Tax withholdingCommon Stock | 5,902 | $5.18 | $30,572.36 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 4 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,871 F2 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Exercise / conversionCommon Stock | 9,378 | $3.26 | $30,572.28 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 3 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Tax withholdingCommon Stock | 15,223 | $5.18 | $78,855.14 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,395 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Exercise / conversionCommon Stock | 20,622 | $3.26 | $67,227.72 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 19:14 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 3,772 | $4.97 | $18,746.84 |
DisclosureSEC source: 0001127602-18-009562 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,902 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 19:11 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 2,012 | $4.97 | $9,999.64 |
DisclosureSEC source: 0001127602-18-009560 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,147 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:23 UTC |
Stonehouse Jon PDirector · President & CEO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 56,949 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-009568 · form4.xml · derivative · entry 3 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,949 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:23 UTC |
Stonehouse Jon PDirector · President & CEO
|
Tax withholdingCommon Stock | 43,224 | $4.97 | $214,823.28 |
DisclosureSEC source: 0001127602-18-009568 · form4.xml · nonDerivative · entry 2 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,092 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:23 UTC |
Stonehouse Jon PDirector · President & CEO
|
Exercise / conversionCommon Stock | 56,949 | $3.26 | $185,653.74 |
DisclosureSEC source: 0001127602-18-009568 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:21 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 6,709 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-009566 · form4.xml · derivative · entry 2 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,709 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:21 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Exercise / conversionCommon Stock | 6,709 | $3.26 | $21,871.34 |
DisclosureSEC source: 0001127602-18-009566 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:12 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Tax withholdingCommon Stock | 1,961 | $5.59 | $10,961.99 |
DisclosureSEC source: 0001127602-18-002237 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,129 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:10 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Tax withholdingCommon Stock | 3,872 | $5.59 | $21,644.48 |
DisclosureSEC source: 0001127602-18-002235 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,996 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:06 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Tax withholdingCommon Stock | 3,979 | $5.59 | $22,242.61 |
DisclosureSEC source: 0001127602-18-002230 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:08 UTC |
Sheridan William PSenior VP - CMO
|
Tax withholdingCommon Stock | 4,628 | $5.59 | $25,870.52 |
DisclosureSEC source: 0001127602-18-002233 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,058 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:03 UTC |
Stonehouse Jon PDirector · President & CEO
|
Tax withholdingCommon Stock | 9,584 | $5.59 | $53,574.56 |
DisclosureSEC source: 0001127602-18-002228 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,367 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.